Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Saniona appoints Carrie Cook as Chief Business Officer

SANIONPress release20.11.2026, 08.00

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on neurological and psychiatric disorders, today announces the appointment of Carrie Cook as Chief Business Officer, CBO. Ms. Cook is an accomplished business development leader with over 25 years of global business development experience across large pharmaceutical and biotechnology companies. She will lead global business development, partnering and alliance management as Saniona advances SAN2668 and SAN2465 toward the clinic.

“We are very pleased to welcome Carrie Cook to Saniona,” said Thomas Feldthus, CEO of Saniona. “Out-licensing helps fund the development of our own pipeline, and our ambition is to partner at least one internally developed asset in the near to medium term. Carrie Cook’s track record of establishing strategic licensing and collaboration agreements with both global pharma and biotech partners will help us deliver on that strategy.”

“Saniona has built a premier ion channel discovery engine, validated by established partnerships with Jazz Pharmaceuticals and Acadia Pharmaceuticals,” said Carrie Cook, CBO of Saniona. “With two proprietary, potentially best-in-class neurology programs nearing Phase 1 trials, Saniona is at an exciting stage in its development, and I look forward to working with Thomas and the team to maximize the potential of these programs.”

Ms. Cook most recently served as Chief Business Officer of Sitryx, where she led and closed a licensing agreement with Boehringer Ingelheim valued at more than USD 500 million.

Previously, Ms. Cook served as Chief Business Officer of Cerevance, a neuroscience biotechnology company, where she led portfolio strategy, business development and alliance management. While at Cerevance, she executed a research collaboration and license agreement with Merck & Co with a total deal value of more than USD 1.1 billion. Earlier in her career, she held business development and commercial roles at CANbridge Pharmaceuticals, Takeda, Merck KGaA through EMD Serono and Merck Serono, Novartis and Baxter.

Carrie Cook holds an MBA from INSEAD and a B.A. in Biotechnology from Duke University. She will join Saniona’s executive leadership team and report to the CEO.

About Saniona
Saniona is a clinical-stage biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders. The company’s internal pipeline includes SAN2668 for pediatric epilepsy syndromes and SAN2465 for major depressive disorder. Saniona has established strategic collaborations with leading pharmaceutical companies, including Jazz Pharmaceuticals, which holds global rights to SAN2355 for epilepsy, Acadia Pharmaceuticals, which holds worldwide rights to ACP-711 for essential tremor, and with Medix, which holds rights to tesofensine for obesity in Mexico, and Argentina. Saniona’s ion channel discovery platform is further validated through research collaborations with Boehringer Ingelheim, Cephagenix and AstronauTx, which holds worldwide rights to ATX0926. Headquartered in Copenhagen, Saniona is listed on the Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.

For more information, please contact
Johnny Stilou, CFO, +45 21227227; johnny.stilou@saniona.com

Attachments
Saniona appoints Carrie Cook as Chief Business Officer